FDA Grants Approval for Lamotrigine ANDA077420 by Rising
The FDA has granted approval for ANDA077420, a generic version of Lamotrigine, submitted by Rising.
Published: July 17, 2026
Updated: July 17, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antiepileptic
Asset: Lamotrigine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Lamotrigine
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of a generic version of Lamotrigine by Rising introduces significant competition in the neurology market. Pharma strategy teams must evaluate the implications for pricing and market share of existing branded products to maintain competitive positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Rising and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.